0
Back To Top Jump Location
Sign In  | Cart
Left Shadow
Right Shadow
Articles |

Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia FREE

Donald A. Chilson, MD; James J. Heger, MD, FACC; Douglas P. Zipes, MD, FACC; Kevin F. Browne, MD; Eric N. Prystowsky, MD, FACC
[+] Author Information

From the Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine and the Roudebush Veterans Administration Medical Center, Indianapolis, Indiana.

Address for reprints: Eric N. Prystowsky, MD, Krannert Institute of Cardiology, 1001 West Tenth Street, Indianapolis, Indiana 46202.

American College of Cardiology Foundation

J Am Coll Cardiol. 1985;5(6):1407-1413. doi:10.1016/S0735-1097(85)80357-0
Published online

  The effects of the antiarrhythmic agent propafenone were evaluated in 25 patients with recurrent symptomatic ventricular tachycardia. Oral propafenone was given to a maximal dose of 300 mg every 8 hours. Ten of the 25 patients developed side effects or had inadequate suppression of spontaneous ventricular arrhythmias during propafenone therapy. Electrophysiologic studies were performed before and during drug therapy on the 15 patients who had a satisfactory clinical response. Propafenone increased the PR interval from 168 ± 46 to 188 ± 25 ms (p < 0.007), the HV interval from 47 ± 10 to 65 ± 13 ms (p < 0.005), the shortest atrial pacing cycle length to maintain 1:1 atrioventricular (AV) nodal conduction from 385 ± 44 to 436 ± 42 ms (p < 0.005), the ventricular effective refractory period from 231 ± 17 to 255 ± 19 ms (p < 0.001) and the ventricular functional refractory period from 260 ± 15 to 278 ± 17 ms (p < 0.002).Before propafenone therapy, all 15 patients had ventricular tachycardia induced by programmed ventricular stimulation. During propafenone treatment, 12 patients still had ventricular tachycardia induced, and the tachycardia cycle length significantly increased from 236 ± 44 to 374 ± 103 ms (p < 0.001). Ten patients were considered to have satisfactory electrophysiologic response to propafenone on the basis of either the inability to initiate ventricular tachycardia or a marked increase in ventricular tachycardia cycle length associated with lack of symptoms during the induced tachycardia. These patients were discharged receiving propafenone. During a mean follow-up period of 11 months, 8 of the 10 patients have remained free of ventricular tachycardia, while 2 have had a recurrence.Propafenone significantly depresses AV nodal and His-Purkinje conduction, lengthens ventricular refractoriness and markedly increases ventricular tachycardia cycle length. Furthermore, preliminary data suggest that induction of ventricular tachycardia at electrophysiologic study does not always augur recurrence of spontaneous tachycardia.

References

Karagueuzian  HS, Fujimoto  T, Katoh  T, Peter  T, McCullen  A, Mandel  WJ; Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent, during acute myocardial infarction in the conscious dog. Circulation. 66 1982:1190-1198.
CrossRef | PubMed
Waleffe  A, Mary-Rabine  L, de Rijbel  R, Soyeur  D, Legrand  V, Kulbertus  HE; Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardia. Eur Heart J. 2 1981:345-352.
PubMed
Beck  OA, Hochrein  H; Kombinierte Anwendung von Propafenon und Lidoflazin bei chronischem Vorhofflimmern und flattern. Dtsch Med Wochenschr. 105 1980:1243-1246.
CrossRef | PubMed
Baedeker  W, Wirtzfeld  A, Sack  D, Oversohl  K; The antiarrhythmic effect of Propafenon in ventricular tachycardias. (Ger) Herz/Kreisl. 9 1977:348-352.
Aldor  E, Haeger  H; Clinical experiences with Propafenon. (Ger) Drug Dev Eval. 1 1977:115-119.
Rutsch  W; The influence of Propafenon on ventricular premature beats. (Ger) Herz/Kreisl. 10 1978:183-186.
Connolly  SJ, Kates  RE, Lebsack  CS, Echt  DS, Mason  JW, Winkle  RA; Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol. 52 1983:1208-1213.
CrossRef | PubMed
Fill  WD, Kuehn  P, Probst  P, Zilcher  H; Use of propafenone in man. Clinical results on the effects on electrophysiological and hemodynamic parameters. Drug Dev Eval. 1 1977:71-79.
Schirop  T, Barckow  D; Clinical experience with propafenone, an antiarrhythmic agent. (Ger) Drug Dev Eval. 1 1977:80-83.
Prystowsky  EN, Jackman  WM, Rinkenberger  RL, Heger  JJ, Zipes  DP; Effect of autonomic blockade on ventricular refractoriness and atrioventricular nodal conduction in man. Evidence supporting a direct cholinergic action on ventricular muscle refractoriness. Circ Res. 49 1981:511-518.
CrossRef | PubMed
Jackman  WM, Prystowsky  EN, Naccarelli  GV; Re-evaluation of enhanced AV nodal conduction: evidence to suggest a continuum of normal AV nodal physiology. Circulation. 67 1983:441-448.
CrossRef | PubMed
Naccarelli  GV, Fineberg  NS, Zipes  DP, Heger  JJ, Duncan  G, Prystowsky  EN; Amiodarone: discriminant analysis successfully predicts clinical outcome in patients who have ventricular tachycardia induced by programmed stimulation (abstr). Circulation. 66 (II) 1982:II-892.
Bazett  HC; An analysis of the time relations of electrocardiograms. Heart. 7 1920:353-370.
Doherty  JU, Waxman  HL, Kienzle  MG; Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation. J Am Coll Cardiol. 4 1984:378-381.
CrossRef | PubMed
Prystowsky  EN, Heger  JJ, Lloyd  EA, Zipes  DP; Clinical electrophyr siology of ventricular tachycardia.Zipes  DP; Cardiac Arrhythmias, Cardiology Clinics. 1983 WB Saunders Philadelphia:253-273.
Heger  JJ, Prystowsky  EN, Jackman  WM; Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 305 1981:539-545.
CrossRef | PubMed

Figures

Tables

Interactive Graphics

Video

References

Karagueuzian  HS, Fujimoto  T, Katoh  T, Peter  T, McCullen  A, Mandel  WJ; Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent, during acute myocardial infarction in the conscious dog. Circulation. 66 1982:1190-1198.
CrossRef | PubMed
Waleffe  A, Mary-Rabine  L, de Rijbel  R, Soyeur  D, Legrand  V, Kulbertus  HE; Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardia. Eur Heart J. 2 1981:345-352.
PubMed
Beck  OA, Hochrein  H; Kombinierte Anwendung von Propafenon und Lidoflazin bei chronischem Vorhofflimmern und flattern. Dtsch Med Wochenschr. 105 1980:1243-1246.
CrossRef | PubMed
Baedeker  W, Wirtzfeld  A, Sack  D, Oversohl  K; The antiarrhythmic effect of Propafenon in ventricular tachycardias. (Ger) Herz/Kreisl. 9 1977:348-352.
Aldor  E, Haeger  H; Clinical experiences with Propafenon. (Ger) Drug Dev Eval. 1 1977:115-119.
Rutsch  W; The influence of Propafenon on ventricular premature beats. (Ger) Herz/Kreisl. 10 1978:183-186.
Connolly  SJ, Kates  RE, Lebsack  CS, Echt  DS, Mason  JW, Winkle  RA; Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol. 52 1983:1208-1213.
CrossRef | PubMed
Fill  WD, Kuehn  P, Probst  P, Zilcher  H; Use of propafenone in man. Clinical results on the effects on electrophysiological and hemodynamic parameters. Drug Dev Eval. 1 1977:71-79.
Schirop  T, Barckow  D; Clinical experience with propafenone, an antiarrhythmic agent. (Ger) Drug Dev Eval. 1 1977:80-83.
Prystowsky  EN, Jackman  WM, Rinkenberger  RL, Heger  JJ, Zipes  DP; Effect of autonomic blockade on ventricular refractoriness and atrioventricular nodal conduction in man. Evidence supporting a direct cholinergic action on ventricular muscle refractoriness. Circ Res. 49 1981:511-518.
CrossRef | PubMed
Jackman  WM, Prystowsky  EN, Naccarelli  GV; Re-evaluation of enhanced AV nodal conduction: evidence to suggest a continuum of normal AV nodal physiology. Circulation. 67 1983:441-448.
CrossRef | PubMed
Naccarelli  GV, Fineberg  NS, Zipes  DP, Heger  JJ, Duncan  G, Prystowsky  EN; Amiodarone: discriminant analysis successfully predicts clinical outcome in patients who have ventricular tachycardia induced by programmed stimulation (abstr). Circulation. 66 (II) 1982:II-892.
Bazett  HC; An analysis of the time relations of electrocardiograms. Heart. 7 1920:353-370.
Doherty  JU, Waxman  HL, Kienzle  MG; Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation. J Am Coll Cardiol. 4 1984:378-381.
CrossRef | PubMed
Prystowsky  EN, Heger  JJ, Lloyd  EA, Zipes  DP; Clinical electrophyr siology of ventricular tachycardia.Zipes  DP; Cardiac Arrhythmias, Cardiology Clinics. 1983 WB Saunders Philadelphia:253-273.
Heger  JJ, Prystowsky  EN, Jackman  WM; Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 305 1981:539-545.
CrossRef | PubMed

Correspondence

Latest JACC CME

Continuing Medical Education through JACC is a convenient way to fulfill your CME requirements while learning important information about the latest advances in cardiovascular medicine.

April 2013- JACC CME Activity
Repeat Revascularization and Outcome

March 2013- JACC CME Activity
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction

Feb 2013- JACC CME Activity
Results from the BARI 2D Trial

Jan 2013- JACC CME Activity
Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope

Dec 2012- JACC CME Activity
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

Nov 2012- JACC CME Activity
A Collaborative Analysis of Individual Patient Data From 10 Randomized Trials

Oct 2012- JACC CME Activity
Radiofrequency Ablation of Premature Ventricular Ectopy Improves the Efficacy of Cardiac Resynchronization Therapy in Nonresponders

Sept 2012- JACC CME Activity
Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease

Aug 2012- JACC CME Activity
Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)

July 2012- JACC CME Activity
Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction

For previous CME quizzes, please follow this link to CardioSource Lifelong Learning and MOC.

 

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles